{"classes":[{"categories":[{"measurements":[{"comment":"Upper confidence limit could not be estimated due to low number of patients with an event.","groupId":"OG000","lowerLimit":"1.9","upperLimit":"NA","value":"16.7"},{"comment":"Upper confidence limit could not be estimated due to low number of patients with an event.","groupId":"OG001","lowerLimit":"9.2","upperLimit":"NA","value":"21.2"},{"comment":"Upper confidence limit could not be estimated due to low number of patients with an event.","groupId":"OG002","lowerLimit":"4.2","upperLimit":"NA","value":"32.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"Duration of response (Kaplan Meier estimates)","dispersionType":"95% Confidence Interval","groups":[{"description":"Treatment cycle 28 days, iv MOR03087 and oral dexamethasone (DEX) applied day 1, 8, 15 \\& 22 plus extra dose on day 4 of cycle 1, initial MOR03087 dose 4 mg/kg, max 16 mg/kg. DEX dose 40 mg (≤ 75 years old) or 20 mg (\\> 75 years old)","id":"OG000","title":"Part C: MOR03087 Plus Dexamethasone"},{"description":"Treatment cycle 28 days, iv MOR03087 and oral dexamethasone (DEX) applied day 1, 8, 15 \\& 22 plus extra dose on day 4 of cycle 1, initial MOR03087 dose 8 mg/kg, max 16 mg/kg. DEX dose 40 mg (≤ 75 years old) or 20 mg (\\> 75 years old). Pomalidomide was administered to patients orally 4 mg on days 1-21 of the 28-day cycle.","id":"OG001","title":"Part D: MOR03087 Plus Pomalidomide + Dexamethasone"},{"description":"Treatment cycle 28 days, iv MOR03087 and oral dexamethasone (DEX) applied day 1, 8, 15 \\& 22 plus extra dose on day 4 of cycle 1, initial MOR03087 dose 8 mg/kg, max 16 mg/kg. DEX dose 40 mg (≤ 75 years old) or 20 mg (\\> 75 years old).\n\nLenalidomide was administered to patients orally 25 mg on days 1-21 of the 28-day cycle.","id":"OG002","title":"Part E: MOR03087 Plus Lenalidomide + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Of the total 91 patients, 26 obtained a response: 5 in part C, 10 in part D and 11 in part E. Duration of response was calculated only in these patients.","reportingStatus":"POSTED","timeFrame":"patients were observed up to 36 months","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}